MyoKardia, Inc
NEWS
MyoKardia, Inc. was acquired by Bristol Myers Squibb (BMS) in 2020.
MyoKardia, Inc. announced that Jake Bauer, Chief Business Officer, will participate in a fireside chat at the 2019 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25th, 2019, at 1:20 p.m. ET in New York, NY.
MyoKardia, Inc., presented data at the European Society of Cardiology Heart Failure Congress from its Phase 1a single-ascending dose study of MYK-491 in healthy volunteers.
MyoKardia, Inc. reported financial results for the quarter ended March 31, 2019.
MyoKardia, Inc. announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15th, 2019, at 8:40 a.m. PT (11:40 a.m. ET) in Las Vegas, NV.
Three Researchers Awarded $250,000 Each to Advance Independent Research in Cardiac Diseases
MyoKardia, Inc. announced that it will report first quarter 2019 financial and operating results on Thursday, May 9, 2019.
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
Thirteen of those were development programs, the remaining 25 research-stage. In September, the company indicated it was on a cost-cutting program, planning to save 1.5 billion euros this year. Of the programs it is dumping, the most prominent is a mid-phase drug for respiratory syncytial virus (RSV), ALX-0171.
Management to Host Conference Call at 8:30 a.m. ET/5:30 a.m. PT
IN THE PRESS